Clinical Trial Update: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study of CNTY-101 in CD19-positive B-cell malignancies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Non-hodgkin Lymphoma
• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CNTY-101

Snippet

Sponsor: Century Therapeutics, Inc. | Conditions: R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma | Phase 1 | Status: TERMINATED